What is the recommended baclofen dosing regimen for managing post‑stroke spasticity?

Baclofen Dosing for Post-Stroke Spasticity

Oral baclofen is NOT FDA-approved for post-stroke spasticity and has limited efficacy, particularly for upper extremity spasticity; when used off-label, start at 5 mg three times daily and titrate slowly to 20-80 mg/day in divided doses, though botulinum toxin injections are the preferred first-line treatment for focal spasticity. 1, 2, 3

Critical FDA Warning

The FDA label explicitly states: "The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions." 1 This is the most important consideration when prescribing baclofen for post-stroke spasticity—you are using it off-label without established efficacy.

Guideline-Based Treatment Algorithm

First-Line Treatment (Not Baclofen)

• Botulinum toxin injections are the Class I, Level A recommendation for both upper and lower limb focal spasticity 2
• The 2025 VA/DoD guidelines downgraded botulinum toxin from "strong for" to "weak for" but still support its use over oral agents 3

When to Consider Oral Baclofen

Oral antispasticity agents (including baclofen) are Class IIa, Level A recommendations for generalized spastic dystonia but come with dose-limiting sedation 2. Consider baclofen when:

• Spasticity is generalized rather than focal
• Botulinum toxin is contraindicated or refused
• Patient cannot access injection therapy

Oral Baclofen Dosing Protocol

Starting Dose

• 5 mg three times daily (15 mg/day total)
• Take with meals to reduce GI upset

Titration Schedule

• Increase by 5 mg per dose every 3 days as tolerated
• Target range: 30-80 mg/day in 3-4 divided doses 3
• Maximum dose: 80 mg/day (higher doses rarely provide additional benefit and increase side effects)

Monitoring During Titration

• Assess spasticity reduction within 24 hours of each dose change 4
• Watch for dose-limiting sedation (occurs in 17% of patients) 5
• Monitor for weakness that may impair antigravity patterns needed for ambulation 6

Evidence-Based Efficacy Expectations

Lower Extremity Response

Research shows oral baclofen has modest effects on lower extremity spasticity:

• Modified Ashworth Scale decreased from 3.5 to 3.2 (statistically significant but clinically minimal) 5
• Average effective dose: 57 mg/day (range 15-120 mg/day) 5
• Responder rate is low—only 3 of 29 patients (10%) showed meaningful clinical response 7

Upper Extremity Response

Oral baclofen shows NO statistically significant effect on upper extremity spasticity in stroke patients 5. This may reflect GABA-B receptor distribution differences.

Critical Safety Considerations

Absolute Contraindications to Abrupt Discontinuation

Never stop baclofen abruptly—hallucinations and seizures can occur 1. When discontinuing:

• Taper dose gradually over 1-2 weeks minimum
• Reduce by 5-10 mg every 3-7 days

Renal Impairment

Baclofen is renally excreted unchanged—reduce dose by 50% if CrCl <30 mL/min and monitor closely for toxicity 1

Functional Deterioration Risk

Major pitfall: In stroke patients who use spasticity-dependent antigravity patterns for walking, baclofen may eliminate the tone they rely on for mobility, causing loss of ambulation ability 6. Before prescribing:

• Assess if patient uses extensor tone for standing/walking
• Consider trial dose to evaluate functional impact
• Warn patient about potential weakness

Pregnancy Considerations

• Category C: Increased omphaloceles in animal studies at 13x human dose 1
• Neonatal withdrawal syndrome reported—if used during pregnancy, taper before delivery 1

Intrathecal Baclofen for Refractory Cases

For severe spasticity unresponsive to oral agents and botulinum toxin:

• Intrathecal baclofen (ITB) is Class IIb, Level A recommendation 2
• Can be considered as early as 3-6 months post-stroke for refractory cases 2
• Screening bolus: 50 mcg intrathecal 8
• Continuous infusion: Start at 2x the effective bolus dose (average maintenance ~268 mcg/day) 8, 4
• Limitation: ITB may still impair functional ambulation in hemiplegic patients who depend on extensor tone 6

Practical Clinical Approach

1. First attempt: Botulinum toxin for focal spasticity (Class I evidence) 2
2. If generalized spasticity: Trial oral baclofen starting 5 mg TID
3. Assess response: Quantitative measurement (Modified Ashworth Scale) at 1 week
4. Titrate cautiously: Increase every 3 days up to 80 mg/day maximum
5. Monitor function: Watch for loss of antigravity patterns or ambulation ability
6. If ineffective at 80 mg/day: Consider ITB referral for pump trial (if ≥3-6 months post-stroke)
7. Never abruptly discontinue: Taper over 1-2 weeks minimum

Key Takeaway

Oral baclofen has marginal efficacy for post-stroke spasticity (particularly upper extremity), is not FDA-approved for this indication, and carries significant risks of sedation and functional deterioration. Botulinum toxin remains superior for focal spasticity, and intrathecal baclofen should be reserved for severe refractory cases. When used, start low (5 mg TID), go slow (increase every 3 days), and monitor closely for both therapeutic response and functional decline.